ZA200103630B - Particles coated with granulated crystalline ibuprofen. - Google Patents
Particles coated with granulated crystalline ibuprofen. Download PDFInfo
- Publication number
- ZA200103630B ZA200103630B ZA200103630A ZA200103630A ZA200103630B ZA 200103630 B ZA200103630 B ZA 200103630B ZA 200103630 A ZA200103630 A ZA 200103630A ZA 200103630 A ZA200103630 A ZA 200103630A ZA 200103630 B ZA200103630 B ZA 200103630B
- Authority
- ZA
- South Africa
- Prior art keywords
- ibuprofen
- particles
- weight
- ethyl cellulose
- coating
- Prior art date
Links
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims description 85
- 229960001680 ibuprofen Drugs 0.000 title claims description 85
- 239000002245 particle Substances 0.000 title claims description 43
- 238000000576 coating method Methods 0.000 claims description 51
- 239000011248 coating agent Substances 0.000 claims description 50
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 34
- 239000001856 Ethyl cellulose Substances 0.000 claims description 32
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 32
- 229920001249 ethyl cellulose Polymers 0.000 claims description 32
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 32
- 239000006185 dispersion Substances 0.000 claims description 31
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 30
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 30
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 30
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000013081 microcrystal Substances 0.000 claims description 21
- 239000000377 silicon dioxide Substances 0.000 claims description 17
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- 230000007928 solubilization Effects 0.000 claims description 10
- 238000005063 solubilization Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- -1 alkali metal salts Chemical class 0.000 claims description 7
- 230000000622 irritating effect Effects 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 229960003511 macrogol Drugs 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 230000000873 masking effect Effects 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 230000009747 swallowing Effects 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 description 26
- 239000007931 coated granule Substances 0.000 description 19
- 238000003756 stirring Methods 0.000 description 10
- 239000008119 colloidal silica Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 239000007970 homogeneous dispersion Substances 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Developing Agents For Electrophotography (AREA)
- Glanulating (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9814033A FR2785539B1 (fr) | 1998-11-06 | 1998-11-06 | Particules enrobees d'ibuprofene cristallin granule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103630B true ZA200103630B (en) | 2002-05-06 |
Family
ID=9532492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103630A ZA200103630B (en) | 1998-11-06 | 2001-05-04 | Particles coated with granulated crystalline ibuprofen. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6951657B1 (pt) |
| EP (1) | EP1126829B1 (pt) |
| JP (1) | JP3987282B2 (pt) |
| KR (1) | KR100586059B1 (pt) |
| CN (1) | CN1154482C (pt) |
| AT (1) | ATE265206T1 (pt) |
| AU (1) | AU765765B2 (pt) |
| BR (1) | BR9915111A (pt) |
| CA (1) | CA2349503C (pt) |
| CZ (1) | CZ292290B6 (pt) |
| DE (1) | DE69916876T2 (pt) |
| DK (1) | DK1126829T3 (pt) |
| EA (1) | EA002897B1 (pt) |
| ES (1) | ES2219073T3 (pt) |
| FR (1) | FR2785539B1 (pt) |
| HK (1) | HK1039890B (pt) |
| HU (1) | HU229936B1 (pt) |
| IL (1) | IL142787A (pt) |
| MX (1) | MXPA01004517A (pt) |
| NZ (1) | NZ511479A (pt) |
| PL (1) | PL194527B1 (pt) |
| PT (1) | PT1126829E (pt) |
| SK (1) | SK283944B6 (pt) |
| TR (1) | TR200101230T2 (pt) |
| WO (1) | WO2000027368A1 (pt) |
| ZA (1) | ZA200103630B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2795962B1 (fr) | 1999-07-08 | 2003-05-09 | Prographarm Laboratoires | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif |
| FR2824477B1 (fr) * | 2001-05-09 | 2005-09-09 | Ethypharm Lab Prod Ethiques | Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes |
| FR2850275B1 (fr) * | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | Capsules molles a macher contenant une substance active a gout masque |
| EP1800667A1 (en) | 2005-12-23 | 2007-06-27 | Losan Pharma GmbH | Rapidly solubilizing ibuprofen granulate |
| AU2006226293B2 (en) * | 2005-03-22 | 2011-04-07 | Losan Pharma Gmbh | Solubilized ibuprofen |
| US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| EP1919288A4 (en) * | 2005-07-18 | 2009-12-16 | Horizon Therapeutics Inc | FAMOTIDINE- AND IBUPROGEN-BASED MEDICAMENTS AND THEIR ADMINISTRATION |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| DE102005049001A1 (de) * | 2005-10-11 | 2007-04-12 | Basf Ag | Verfahren zur Herstellung von direkttablettierbaren Ibuprofen-Formulierungen |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| ATE553755T1 (de) * | 2006-07-27 | 2012-05-15 | Univ Sunderland | Stärke enthaltende beschichtungszusammensetzung |
| TWI564008B (zh) | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
| WO2014198999A1 (en) * | 2013-06-13 | 2014-12-18 | Opes Corporation Oy | Matrix |
| US9474699B2 (en) * | 2014-03-31 | 2016-10-25 | Johnson & Johnson Consumer Inc. | Compostions and methods for enhancing the topical application of a basic benefit agent |
| WO2016081783A1 (en) * | 2014-11-19 | 2016-05-26 | Kiromic, Llc | Novel nanoparticle-based vaccine targeting cancer/testis antigens (cta) and its use in solid and hematological malignancies |
| WO2019080693A1 (zh) | 2017-10-26 | 2019-05-02 | 浙江越甲药业有限公司 | 一种稳定的含有非甾体抗炎药衍生物的药物组合物 |
| AU2020225818A1 (en) | 2019-02-22 | 2021-10-14 | Catalent U.K. Swindon Zydis Limited | Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension |
| GB2597577B (en) | 2019-02-22 | 2023-09-20 | Catalent Uk Swindon Zydis Ltd | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen |
| CN113453662A (zh) * | 2019-02-22 | 2021-09-28 | 康特伦英国斯温顿捷迪斯有限公司 | 储存期间药物颗粒包衣材料的团聚最小化以稳定化药物产品的崩解时间 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4308251A (en) * | 1980-01-11 | 1981-12-29 | Boots Pharmaceuticals, Inc. | Controlled release formulations of orally-active medicaments |
| US4588612A (en) * | 1985-04-24 | 1986-05-13 | Scm Corporation | Pretreatment in encapsulation process |
| GB8519310D0 (en) * | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
| US4835186A (en) | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
| US4835187A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
| US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
| NZ234587A (en) * | 1989-08-04 | 1991-11-26 | Mcneil Ppc Inc | A chewable pharmaceutical tablet of compressed coated granules |
| IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| CA2076983A1 (en) * | 1990-04-11 | 1991-10-12 | Robert Wu-Wei Shen | Taste masking of ibuprofen by fluid bed coating |
| FR2679451B1 (fr) * | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| US5191114A (en) * | 1991-10-09 | 1993-03-02 | Sage Pharmaceuticals, Inc. | Process for enhancing the flow characteristics of ibuprofen |
| ZA945944B (en) * | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
-
1998
- 1998-11-06 FR FR9814033A patent/FR2785539B1/fr not_active Expired - Lifetime
-
1999
- 1999-11-03 WO PCT/FR1999/002682 patent/WO2000027368A1/fr active IP Right Grant
- 1999-11-03 EP EP99954047A patent/EP1126829B1/fr not_active Expired - Lifetime
- 1999-11-03 US US09/830,101 patent/US6951657B1/en not_active Expired - Lifetime
- 1999-11-03 BR BR9915111-1A patent/BR9915111A/pt not_active Application Discontinuation
- 1999-11-03 DK DK99954047T patent/DK1126829T3/da active
- 1999-11-03 PT PT99954047T patent/PT1126829E/pt unknown
- 1999-11-03 PL PL99347549A patent/PL194527B1/pl unknown
- 1999-11-03 MX MXPA01004517A patent/MXPA01004517A/es active IP Right Grant
- 1999-11-03 ES ES99954047T patent/ES2219073T3/es not_active Expired - Lifetime
- 1999-11-03 NZ NZ511479A patent/NZ511479A/xx not_active IP Right Cessation
- 1999-11-03 TR TR2001/01230T patent/TR200101230T2/xx unknown
- 1999-11-03 AT AT99954047T patent/ATE265206T1/de active
- 1999-11-03 HU HU0104394A patent/HU229936B1/hu unknown
- 1999-11-03 CN CNB998138002A patent/CN1154482C/zh not_active Expired - Lifetime
- 1999-11-03 KR KR1020017005749A patent/KR100586059B1/ko not_active IP Right Cessation
- 1999-11-03 SK SK566-2001A patent/SK283944B6/sk not_active IP Right Cessation
- 1999-11-03 DE DE69916876T patent/DE69916876T2/de not_active Expired - Lifetime
- 1999-11-03 AU AU10508/00A patent/AU765765B2/en not_active Expired
- 1999-11-03 EA EA200100491A patent/EA002897B1/ru not_active IP Right Cessation
- 1999-11-03 CA CA2349503A patent/CA2349503C/fr not_active Expired - Fee Related
- 1999-11-03 JP JP2000580599A patent/JP3987282B2/ja not_active Expired - Lifetime
- 1999-11-03 CZ CZ20011434A patent/CZ292290B6/cs not_active IP Right Cessation
-
2001
- 2001-04-25 IL IL142787A patent/IL142787A/en not_active IP Right Cessation
- 2001-05-04 ZA ZA200103630A patent/ZA200103630B/en unknown
-
2002
- 2002-02-01 HK HK02100786.6A patent/HK1039890B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU765765B2 (en) | Particles coated with granulated crystalline ibuprofen | |
| JP4749639B2 (ja) | 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法 | |
| US5670172A (en) | Pharmaceutical spheroid formulation | |
| JP3961217B2 (ja) | 抗潰瘍活性化合物を含んでなる経口医薬製剤およびその製造方法 | |
| CA2539982C (en) | Pantoprazole multiparticulate formulations | |
| JP2002523443A (ja) | オメプラゾール製剤 | |
| PL174178B1 (pl) | Preparat farmaceutyczny w postaci kapsułek zawierających kulki | |
| HRP20010463A2 (en) | Controlled release galantamine composition | |
| JP4234427B2 (ja) | 活性成分をベースとする微小顆粒およびその製造方法 | |
| CA2684586A1 (en) | High dose composition of ursodeoxycholic acid | |
| PL186386B1 (pl) | Sposób wytwarzania granulatu zawierającego aktywny przy podawaniu drogą doustną antybiotyk beta-laktamowy oraz sposób wytwarzania szybko rozpadającejsię postaci dawkowania zawierającej aktywny przy podawaniu drogą doustną antybiotyk beta-laktamowy | |
| JP4447166B2 (ja) | 硫酸モルヒネマイクロ顆粒剤、製法および医薬調製物 | |
| WO2004087111A1 (en) | Oral taste masked pharmaceutical compositions | |
| WO2000076479A1 (en) | Taste masked compositions | |
| WO2003070223A1 (fr) | Preparations a liberation lente et methode de production desdites preparations | |
| CN114340601A (zh) | 掩盖了令人不快的味道的颗粒剂及其制造方法 | |
| CZ288028B6 (cs) | Způsob výroby lékové formy obsahující karbamazepin se zpožděným uvolňováním účinné látky | |
| WO2007096902A2 (en) | Solid oral dosage forms of griseofulvin | |
| WO2001076607A1 (fr) | Sirop sous forme de substance seche renfermant des microcapsules de theophylline a liberation prolongee | |
| GB2258613A (en) | Pharmaceutical diltiazem spheroid formulation | |
| TWI278326B (en) | Aspirin controlled-release granule capsule | |
| JP2006131673A (ja) | 徐放化組成物及びその製造方法 |